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Abstract In a few rare diseases, specialised studies in
cerebrospinal fluid (CSF) are required to identify the
underlying metabolic disorder. We aimed to explore the
possibility of detecting key synaptic proteins in the CSF, in
particular dopaminergic and gabaergic, as new procedures
that could be useful for both pathophysiological and
diagnostic purposes in investigation of inherited disorders
of neurotransmission. Dopamine receptor type 2 (D2R),
dopamine transporter (DAT) and vesicular monoamine
transporter type 2 (VMAT2) were analysed in CSF samples
from 30 healthy controls (11 days to 17 years) by western
blot analysis. Because VMAT2 was the only protein with
intracellular localisation, and in order to compare results,
GABA vesicular transporter, which is another intracellular
protein, was also studied. Spearman’s correlation and
Student’s t tests were applied to compare optical density
signals between different proteins. All these synaptic
proteins could be easily detected and quantified in the
CSF. DAT, D2R and GABA VT expression decrease with
age, particularly in the first months of life, reflecting the
expected intense synaptic activity and neuronal circuitry
formation. A statistically significant relationship was found
between D2R and DAT expression, reinforcing the previous
evidence of DAT regulation by D2R. To our knowledge, there
are no previous studies on human CSF reporting a reliable
analysis of these proteins. These kinds of studies could help
elucidate new causes of disturbed dopaminergic and gabaergic
transmission as well as understanding different responses to
L-dopa in inherited disorders affecting dopamine metabolism.
Moreover, this approach to synaptic activity in vivo can be
extended to different groups of proteins and diseases.
Introduction
Specialised investigations in cerebrospinal fluid can be
crucial to identify some inborn errors of metabolism.
Defects of biogenic amines (dopamine and serotonine),
GABA and glycine make up the group of diseases that are
currently considered to be inborn errors of neurotransmitters.
In these disorders, quantification of some particular CSF
metabolites (biogenic amines, GABA or glycine) is necessary
in the diagnostic process. However, although growing
evidence suggests that genetic or pathologic alterations of
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proteins involved in synaptic transmission may underlie a
number of neurological and psychiatric disorders (Südhof and
Malenka 2008; Südhof 2008; Witzmann et al. 2005;
Corradini et al. 2009; Kauer and Malenka 2007), the study
of these proteins is not normally included in the array of
investigations carried out in disorders of this kind. In vivo
measurement of synaptic activity is difficult to carry out in
humans. CSF samples are easily accessible by standard
lumbar puncture techniques. Additionally, biochemical
changes in CSF may reflect pathological alteration of CNS
physiology, as previously demonstrated (Ormazabal et al.
2005). Accordingly, CSF receives a wide variety of molecules
released by different CNS cell populations (Thouvenot et al.
2008). Several authors, including some from our group, have
shown that there is a strong variability of CSF biogenic
amines with age in children not suffering neurologic disease
(Ormazabal et al. 2005), which suggests that the same
variability may be expected when analysing synaptic proteins
related to classical neurotransmitter function.
Synaptic transmission depends on neurotransmitter pools
stored within vesicles that undergo regulated exocytosis. In
the case of dopaminergic transmission, the vesicular
monoamine transporter-2 (VMAT2) is responsible for the
loading of dopamine (DA) and other monoamines into
synaptic vesicles (Cartier et al. 2010). The DA transporter
(DAT) carries DA across the plasmalemmal membrane
from the synaptic cleft into the cytoplasm (Volz et al. 2009).
The central actions of DA are mediated by five distinct
receptors that belong to the G-protein receptor family. They
are classified as D1-like (D1 and D5) and D2-like (D2, D3
and D4), and their interaction with dopamine translates into
activation/inhibition of specific neurons and circuitries (De
Mei et al. 2009). Those suffering D2 receptor (D2 R)
genetic mutations exhibit postural abnormalities, bradykinesia
with delayed initiation of movements, impaired coordination
and prolonged periods of immobility (Glickstein and Schmauss
2001). These symptoms are also characteristic of patients
suffering from dopaminergic neurotransmission disorders.
In spite of the critical role of these proteins in dopaminergic
transmission (Fig. 1), information about procedures for
studying them in CSF is very scarce, to our knowledge.
However, such knowledge would be useful to increase
understanding of the mechanisms of disturbed dopaminergic
transmission in primary (inherited disorders of dopamine)
and secondary deficiencies.
We aimed to analyse, in the CSF of a control
population, the synaptic proteins VMAT2, DAT and D2
R. Because VMAT2 was the only protein with intracel-
lular localisation, GABA vesicular transporter (GABA
VT), which is another intracellular protein, was also
included in the study. We evaluated the correlation of
these proteins with each other and with the age of
controls. Additionally, because total CSF protein concen-
tration is known to decrease with age, we introduced this
variable in the age correlation studies.
Methods
CSF samples
The study was performed in 30 subjects (age range:
11 days–17 years; average: 1.8 years) whose CSF samples
were submitted to Hospital San Joan de Déu laboratory for
analysis under suspicion of viral or bacterial meningitis or
encephalitis. Lumbar puncture was performed in the
emergency room, and the first ten drops were used for
routine cytochemical/microbiological studies. Inflammatory
markers (C-reactive protein and procalcitonin) were also
analysed. Exclusion criteria were diagnosis of viral or
bacterial meningitis, a chronic neurological condition, and
hematic or xanthochromic CSF (blood contamination).
Samples from patients were obtained in accordance with
the Helsinki Declaration of 1964, as revised in 2000. The
ethical committee of the Hospital Sant Joan de Déu
approved the study. After collection, samples were stored
at −80°C up to the moment of the analysis.
Western blot
Western blot analysis was performed for each protein (DAT,
D2 R, VMAT2, GABA VT). A sample of 20 μL of CSF
was loaded into the gel and proteins were separated on 10%
sodium dodecyl sulphate-polyacrylamide gels and trans-
ferred to polyvinylidene difluoride (PVDF) membranes
(Amersham™ Hybond™–ECL; GE Healthcare). The mem-
VMAT 2
DAT
D2 receptor
Fig. 1 Schematic representation of the dopaminergic synapse,
illustrating the link between VMAT2 (vesicular monoamine transporter
2), DAT (dopamine transporter ) and D2 R (D2 receptor)
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branes were incubated in TBST buffer (0.02 M Tris-base,
pH7.6, 0.8% NaCl, 0.1% Tween 20) supplemented with 5%
dried skimmed milk for 60 min to block non-specific
binding. Anti-DAT extracellular loop (1:1,000; Sigma®),
anti-D2 R (1:1,000; Millipore®), anti-VMAT 2 (1:1,000;
Santa Cruz Biotechnology®), and anti-GABA VT (1:500;
Millipore®) antibodies were added, and the preparations were
incubated at 4°C overnight. The membranes were washed three
times with TBST buffer and then incubated with appropriate
anti-rabbit (1:3,000; Promega®) or anti-mouse (1:5,000;
Promega®) IgG secondary antibodies at room temperature for
1 h. The blot was then washed six times with TBST and
prepared with ECL (Pierce® ECLWestern Blotting Substract;
Thermo Scientific) for developing. Relative levels of each
protein were quantified by measuring optical densities (OD) of
the corresponding bands with Quantity One® V 4.3.1.
software.
CSF total protein concentration, procalcitonin
and C-reactive protein determination
CSF total protein and C-Reactive Protein concentrations
were measured by standard automated procedures in an
Architect ci8200 analyser (Abbott, USA). Procalcitonin
was measured by fluorimetric detection, with Brahams-
Kryptor-Atom® analyser.
Statistical analysis
Statistical analysis was performed with the SPSS 17.0
program. Spearman’s correlation test was applied to search
for associations among the OD signals of the different
proteins and with the age of controls. Multivariate linear
regression analysis was used to adjust the results by total
CSF protein concentration. Student’s t test was applied to
compare OD signals of the different proteins according to
gender. Statistical significance was considered as p<0.05.
Results
DAT, D2R, VMAT2 and GABA vesicular transporter were
clearly detectable at different ages using conventional western
blot analysis in all the CSF samples studied (Fig. 2).
VMAT2 expression measured as OD showed a statistically
significant negative correlation with age (Table 1.). Correlation
between DAT expression and age showed a strong tendency
to significance (p value=0.05). D2R expression and GABA
vesicular transporter expression did not show statistical
association with age when all the CSF samples were included
in the statistical study. However, since our sample population
was predominantly younger than 200 days (for age distribution,
see Fig. 3), we searched for a correlation between D2R and
GABA VT expression with age in this group. A significant
negative correlation was found for D2R and GABA VT. In
order to rule out interference of the expected decrease in total
CSF protein concentration with age, we adjusted these results
by total CSF protein concentration (range, 7–77 g/l; mean,
34.7; median, 31; standard deviation, 17.2. All values were
within normal limits according to different age ranges (Biou
et al. 2000)). Except for VMAT2, the relation between age
and expression of these synaptic proteins remained statistically
significant (Table 1).
No differences were observed when we compared DAT,
D2, VMAT2 and GABA VT protein expression according
to gender.
Concerning association studies among the different proteins,
OD signal of CSF, D2R, and DAT showed a statistically
significant positive correlation (Spearman’s rho correlation test
r=0.016; p=0.443), while no correlation was found between
D2 R and VMAT, or between DAT and VMAT.
Because VMAT2 is also involved in adrenaline and
noradrenaline transport, and its release can be triggered by
acutely stressful situations, we also tried to correlate
VMAT2 expression with acute phase reactants (C-reactive
protein and procalcitonin), in order to rule out the possible
influence of fever or acute disease in the expression of this
protein, since our control population was selected from a
group of children under suspicion of an active infectious
process. C-reactive protein and procalcitonin levels were
Fig. 2 D2, DAT, VMAT and GABAVT detection in the CSF by
western blot in different control samples (a), and a representation of
them according to age ranges (b)
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not related to total CSF protein concentration, nor with
VMAT 2 expression.
Discussion
We aimed to explore the possibility of detecting key
dopaminergic and gabaergic synaptic proteins in a control
population of children. To our knowledge, this is the first
report of detection of these proteins in CSF in a paediatric
population.
In spite of their low abundance compared to global CSF
proteome (Thouvenot et al. 2008), the intensity and
definition of the different bands obtained with the present
procedure (Fig. 1) lends strong support to the applicability
of this analysis in neurochemical research.
Fig. 3 Upper left Population age distribution. Upper middle, upper right, lower left, lower middle Correlation between age and synaptic proteins.
Lower right Correlation between DAT and D2
Table 1 Statistical data of the results for the synaptic proteins studied
D2 R DAT VMAT2 GABAVT
Mean (OD measure) 580,755.5 825,805.8 654,848.24 945,490.3
Standard deviation (OD measure) 302,541.9 598,210.0 385,135.9 356,870.5
Upper Limit (OD measure) 112,6336 211,5196 50,255 1,582,609
Lower Limit (OD measure) 99,224.4 87,053.87 1,574,680 395,287.83
Spearman’s Rho correlation test
between age and OD measure
r=−0.591; p=0.01
(if age under 200 days)
r=−0.329; p=0.05 r=−0.532; p=0.002 r=−0.681; p=0.002
(if age under 200 days)r=−0.482; p=0.015
(if age under 200 days)
Coefficients of a multivariate linear
regression model adjusted by
total protein concentration
β=−6139.738; p=0.007
(if age under 200 days)
β=16.294; p=0.834 β=−28.736; p=0.358 β=−5,886.624; p=0.001
(if age under 200 days)β=−8,119.042; p=0.016
(if age under 200 days)
Optic densities are expressed in arbitrary units
D2R D2 receptor, DAT dopamine transporter, VMAT2 vesicular monoamine transporter 2, GABA VT GABA vesicular transporter, OD optic
density
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The presence of transmembrane synaptic proteins in
CSF can be explained in several ways. It has been
suggested that membrane protein detection is the consequence
of extensive protease actions that cleave the fragments from
proteins that are embedded in membranes, and that these
fragments enter the CSF (Egaña et al. 2009; Zougman et al
2008). However, our study demonstrates that these proteins
are detected at the expected molecular weight, indicating
that there is no fragmentation, or at least that they are
intact in part. Harrington et al. (2009) identified the
presence of CSF membranous nanostructures, thought to
play a physiologically active role, and not merely the
result of blebbing, apocrine secretion, or apoptosis events,
or cellular debris. These structures can provide an
appropriate environment for transmembrane proteins
which are hydrophobic in nature. Their morphology is
similar to that of synaptic vesicles and exosomes; their
structure resembles that of nanotubules, cell-to-cell inter-
actions that facilitate the selective transfer of membrane
vesicles and organelles but which seem to impede the flow
of small molecules (Rustom et al. 2004). In the first
months of life, a period of intense synaptogenesis and
neuronal circuitry formation, cell-to-cell exchange of
synaptic machinery is thought to be carried out by small
dense core vesicles (∼80 nm) (Sorra et al. 2006).
However, extracellular localisation of these structures is not
well documented.
Based on our previous experience with the quantification
of biogenic amines in a population of children without
neurological disease (Ormazabal et al. 2005) who exhibited
a decrease from the first days of life until reaching adult
age, we aimed to learn whether the same tendency was
observed with the synaptic proteins included in the study.
For DAT, D2R and GABAVT, it was possible to establish
a statistically significant relationship, particularly in the
group of children under 6 months of age from whom
most of our sample was drawn. Age-related changes in
DAT functionally active protein have been described in
rats (Volz et al. 2009), showing a decrease between young
adolescent rat levels and adult levels. Interestingly, in the
same report, no difference between VMAT 2 immunore-
activity in the two groups was found, although conflicting
data had previously been published (Volz et al. 2006).
Furthermore, because VMAT2 is involved in fast neuro-
transmission, its regulation could appear to be related to
rapid communication needs and not to age. Another result
that deserves discussion is the relationship discovered
between D2 and DAT expression. Numerous studies have
supported the notion that DAT is subjected to dynamic
regulation in the plasma membrane, and this regulation has
been extensively reviewed by Eriksen et al. (2010). There is
strong evidence that D2 R causes an increase in dopamine
uptake through an increase in DAT surface expression.
Additionally, loss of D2R/DAT co-immunoprecipitation has
been described in schizophrenia, suggesting a role for the
loss of the interaction in the disease process (Bolan et al.
2007).
Currently, investigations are underway of CSF in relation
to disorders of suspected neurometaolic origin; these
include examination of cytochemistry (cells, glucose,
proteins), lactate, amino acids, biogenic amine metabolites,
pterins and 5-methyltetrahydrofolate. However, only a few
disorders can be detected by means of these analyses
(García-Cazorla et al. 2010). Furthermore, the diagnosis of
monogenic defects of dopaminergic neurotransmission is
almost exclusively based on the quantitative determination
of their metabolites in CSF (Marín-Valencia et al. 2008).
Secondary deficiencies of dopamine are found in about
10% of patients who undergo a lumbar puncture in the
diagnostic work-up of a suspected neurometabolic disorder
(García-Cazorla et al. 2007; Van Der Heyden et al. 2003).
Disorders such as mitochondrial diseases (García-Cazorla
et al. 2008) and Lesch-Nyhan disease (Serrano et al. 2008)
are amongst the main known causes of secondary deficiencies.
The analysis of these and other synaptic proteins is expected
to be useful to both increased understanding of the mecha-
nisms of disturbed neurotransmission and identification of
new causes of dopaminergic defects. Concerning primary
deficiencies such as tyrosine hydroxylase deficiency, this
approach could be useful to improving the understanding
of the variable response that patients have to L-dopa
therapy (from normalisation to almost absent effect)
(Willemsen et al. 2010), but we need further data to
document this hypothesis.
To conclude, we report the detection of transmembrane
synaptic proteins in the CSF of a population of children
without neurological disorders. This approach was made as
a means of monitoring neurotransmitter genetic disease
outcome and response to treatment, but its applications can
be extended to the investigation of a growing group of
neurological and psychiatric disorders related to neuro-
transmission. The proteins included in this study were
chosen because of their relevance for dopaminergic and
gabaergic transmission, but there are many other proteins of
interest that can be selected for analysis with this
methodology.
The findings reported here deserve further investigation,
especially in the field of CSF-neuron and inter-cellular
interactions, in order to better understanding of their
physiological implications in the developing brain and
their pathophysiological role in disease states. Significant
correlation with age was found with D2R, DAT and
GABA VT expression, as expected from the previously
reported decrease of biogenic amines in a paediatric
population. Coordinated regulation of DAT by stimulation of
D2 R is further reinforced by our results.
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